Assuntos
Diabetes Mellitus/terapia , Ensaios Clínicos Pragmáticos como Assunto , Saúde Pública , Pesquisa Biomédica/métodos , Ciência de Dados , Complicações do Diabetes/prevenção & controle , Complicações do Diabetes/terapia , Diabetes Mellitus/prevenção & controle , Humanos , Ensaios Clínicos Pragmáticos como Assunto/métodosRESUMO
PURPOSE: The role of multidisciplinary care (MDC) on cancer care processes is not fully understood. We investigated the impact of MDC on the processes of care at cancer centers within the National Cancer Institute Community Cancer Centers Program (NCCCP). METHODS: The study used data from patients diagnosed with stage IIB to III rectal cancer, stage III colon cancer, and stage III nonsmall-cell lung cancer at 14 NCCCP cancer centers from 2007 to 2012. We used an MDC development assessment toolwith levels ranging from evolving MDC (low) to achieving excellence (high)to measure the level of MDC implementation in seven MDC areas, such as case planning and physician engagement. Descriptive statistics and cluster-adjusted regression models quantified the association between MDC implementation and processes of care, including time from diagnosis to treatment receipt. RESULTS: A total of 1,079 patients were examined. Compared with patients with colon cancer treated at cancer centers reporting low MDC scores, time to treatment receipt was shorter for patients with colon cancer treated at cancer centers reporting high or moderate MDC scores for physician engagement (hazard ratio [HR] for high physician engagement, 2.66; 95% CI, 1.70 to 4.17; HR for moderate physician engagement, 1.50; 95% CI, 1.19 to 1.89) and longer for patients with colon cancer treated at cancer centers reporting high 2MDC scores for case planning (HR, 0.65; 95% CI, 0.49 to 0.85). Results for patients with rectal cancer were qualitatively similar, and there was no statistically significant difference among patients with lung cancer. CONCLUSION: MDC implementation level was associated with processes of care, and direction of association varied across MDC assessment areas.
Assuntos
Neoplasias/diagnóstico , Neoplasias/terapia , Equipe de Assistência ao Paciente , Assistência ao Paciente , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Institutos de Câncer , Terapia Combinada , Feminino , Fidelidade a Diretrizes , Humanos , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Neoplasias/epidemiologia , Assistência ao Paciente/métodos , Assistência ao Paciente/normas , Planejamento de Assistência ao Paciente , Estudos Prospectivos , Estudos Retrospectivos , Tempo para o Tratamento , Adulto JovemAssuntos
Continuidade da Assistência ao Paciente/organização & administração , Oncologia/organização & administração , Neoplasias/terapia , Administração dos Cuidados ao Paciente/organização & administração , Assistência Centrada no Paciente/organização & administração , Qualidade da Assistência à Saúde , Canadá , Institutos de Câncer/organização & administração , Previsões , Pesquisa sobre Serviços de Saúde , Humanos , Comunicação Interdisciplinar , Oncologia/métodos , Administração dos Cuidados ao Paciente/métodos , Equipe de Assistência ao Paciente , Assistência Centrada no Paciente/métodos , Atenção Primária à Saúde/métodos , Atenção Primária à Saúde/organização & administração , Projetos de Pesquisa , Meio Social , Estados UnidosRESUMO
Assessment and management of dyspnea has emerged as a priority topic for quality evaluation and improvement. Evaluating dyspnea quality of care requires valid, reliable, and responsive measures of the care provided to patients across settings and diseases. As part of an Agency for Healthcare Research and Quality Symposium, we reviewed quality of care measures for dyspnea by compiling quality measures identified in systematic searches and reviews. Systematic reviews identified only three existing quality measurement sets that included quality measures for dyspnea care. The existing dyspnea quality measures reported by retrospective evaluations of care assess only four aspects: dyspnea assessment within 48 hours of hospital admission, use of objective scales to rate dyspnea severity, identification of management plans, and evidence of dyspnea reduction. To begin to improve care, clinicians need to assess and regularly document patient's experiences of dyspnea. There is no consensus on how dyspnea should be characterized for quality measurement, and although over 40 tools exist to assess dyspnea, no rating scale or instrument is ideal for palliative care. The panel recommended that dyspnea assessment should include a measure of intensity and some inquiry into the associated bother or distress experienced by the patient. A simple question into the presence or absence of dyspnea would be unlikely to help guide therapy, as complete relief of dyspnea in advanced disease would not be anticipated. Additional knowledge gaps include standards for clinical dyspnea care, assessment in the cognitively impaired, and evaluation of effectiveness of dyspnea care for patients with advanced disease.